Why It Matters

The 23andMe Research Institute is entering the federal lobbying arena at a fraught moment. The research arm of the bankrupt genetic testing company has filed a new lobbying registration with Ballard Partners LLC, a well-connected Washington firm, to lobby on medical and disease research. The move signals an effort to shape federal policy on genetic data and research at precisely the moment Congress is scrutinizing the company most closely.

By the Numbers

The registration, filed May 19, 2026 and signed June 10, 2026, lists no dollar amount, as is standard for initial new client registrations. The lobbying registration covers a single issue area: Medical/Disease Research/Clinical Labs. No specific legislation or issues are listed in the disclosure. There are, however, several active and recently enacted bills relevant to the space, including the Don't Sell My DNA Act, the BIOSECURE Act, and the SECURE Data Act.

Broader Context

The registration lands exactly one year after Congress convened simultaneous hearings in both chambers on 23andMe's bankruptcy and the fate of genetic data belonging to roughly 15 million Americans. The company's collapse triggered a bipartisan firestorm over whether sensitive consumer DNA could be sold to the highest bidder, including potentially to foreign adversaries. The BIOSECURE Act, which restricts genetic data flows to adversarial nations, passed into law in December 2025 as part of the National Defense Authorization Act. That legislative backdrop is the environment into which 23andMe Research Institute is now stepping.

Congressional activity on genetic data and medical research has been substantial. On June 10, 2025, Rep. James Comer (R-KY-1) warned of hostile actors gaining access to American DNA through the bankruptcy. In the Senate, Sen. Amy Klobuchar (D-MN) led a Senate Judiciary subcommittee hearing, where she promoted the Don't Sell My DNA Act, a bipartisan bill requiring consumer consent before genetic data can be sold in bankruptcy proceedings. Sen. Chuck Grassley (R-IA) co-sponsored the bill, warning that the data could be used for blackmail or by foreign adversaries.

Separately, Sen. Shelley Moore Capito (R-WV) introduced bipartisan legislation in January 2026 to expand Medicare coverage for genetic counseling services, a sign that Congress is also moving on access-oriented genetic policy, not just restrictions.

The Bottom Line

The 23andMe Research Institute's new lobbying registration, filed through Ballard Partners, is a first-time entry into federal lobbying at a moment of acute congressional attention. The team assembled, with deep Appropriations and health policy experience, reflects the regulatory complexity the institute faces. With legislation targeting genetic data practices advancing in both chambers, and the BIOSECURE Act already law, the institute's choice to register under medical research rather than privacy or cybersecurity suggests a deliberate effort to frame its federal engagement around research value.

Spot something wrong? Report an issue with this article